Elisabeth Douglas Galsgaard

This paper identifies a four-protein proteomic signature that predicts progression to decompensated cirrhosis with high accuracy in both training and external validation cohorts.

This study evaluates Gremlin-1 as a therapeutic target in MASH fibrosis, finding it upregulated but not amenable to targeting due to its restricted expression and lack of effect on fibrogenesis.